Internet Computer ICP

Bitcoin Cash BCH

Litecoin LTC

Poolbeg Pharma PLC

POLBF

Current price

0.15 USD 0 USD (0.00%)

Last closed 10.9 GBX

Company www.poolbegpharma.com

ISIN GB00BKPG7Z60

Sector Healthcare

Industry Biotechnology

Exchange LSE

Capitalization 55 760 719 GBX

Yield for 12 month +51.51 %

10Y

15Y

POLBF

21.11.2021 - 28.11.2021

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom. Address: 40 Bank Street, London, United Kingdom, E14 5NR

Check your investment idea

Find the best to beat the market

TSLA Tesla Motors

AAPL Apple

MSFT Microsoft

Activate

View

Activate

View

Analytics

WallStreet Target Price

1 591.11 GBX

P/E ratio

–

Dividend Yield

–

Revenue
Profit

Current Year

–

Last Year

–

Current Quarter

–

Last Quarter

–

Current Year

-2 577 373 GBX

Last Year

-2 577 373 GBX

Current Quarter

-1 288 724 GBX

Last Quarter

–

1 year

3 years

5 years

10 years

21.11.2021 - 28.11.2021

EBITDA -4 619 450 GBX

Operating Margin TTM –

PE Ratio –

Return On Assets TTM -16.87 %

PEG Ratio –

Return On Equity TTM -24 %

Wall Street Target Price 1 591.11 GBX

Revenue TTM –

Book Value 0.029 GBX

Revenue Per Share TTM

Dividend Share –

Quarterly Revenue Growth YOY –

Dividend Yield –

Gross Profit TTM –

Earnings per share -0.0099 GBX

Diluted Eps TTM -0.0099 GBX

Most Recent Quarter IV 2023

Quarterly Earnings Growth YOY –

Profit Margin –

Dividend growth over 5 years

–

Continuous growth

–

Payout Ratio 5 years average

–

1 year

3 years

5 years

10 years

21.11.2021 - 28.11.2021

Forward Annual Dividend Rate –

Ex Dividend Date –

Forward Annual Dividend Yield –

Last Split Factor –

Payout Ratio –

Last Split Date –

Dividend Date –

1 year

3 years

5 years

10 years

21.11.2021 - 28.11.2021

Trailing PE –

Forward PE –

Enterprise Value Revenue –

Price Sales TTM –

Enterprise Value EBITDA -6.5923

Price Book MRQ 3.8949

Financials POLBF

1 year

3 years

5 years

10 years

15 years

Track key metrics for each stock in one place without the hassle

Get Premium

Results	2019	Dynamics

* The data for this period has not yet been published

6.32 GBX 15.63 GBX

50 Day MA 12.43 GBX

Shares Short Prior Month –

200 Day MA 10.97 GBX

Short Ratio –

Shares Short –

Short Percent –

	All time	January, 22	February, 22	March, 22	April, 22	May, 22	June, 22
Companies with BMS 90+	+10.12%	-1.11%	-1.11%	-1.11%	-1.11%	-1.11%	-1.11%
Companies with BMS 60-	+10.12%	-1.11%	-1.11%	-1.11%	-1.11%	-1.11%	-1.11%

Similar to

Poolbeg Pharma PLC